3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-0f82d34644412e97.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-0f82d34644412e97.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"Image"]
9:I[5864,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","185","static/chunks/app/layout-24f8abeacb8025a3.js"],"default"]
2:T579,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does NEU do?","acceptedAnswer":{"@type":"Answer","text":"Neuren Pharmaceuticals is an Australian biotechnology company focused on developing treatments for rare neurological disorders. Their lead product, trofinetide (DAYBUEâ„¢), is approved in the US for Rett syndrome and generates royalty income, while their pipeline candidate, NNZ-2591, is in clinical trials for other neurodevelopmental conditions."}},{"@type":"Question","name":"Is NEU a good investment?","acceptedAnswer":{"@type":"Answer","text":"Neuren represents a high-growth opportunity, having successfully commercialised its first drug, which provides a strong revenue stream. However, as a biotech company, its valuation is highly dependent on the success of its NNZ-2591 clinical trials, which carries significant binary risk. Investors should weigh the substantial upside potential from pipeline success against the inherent risks of clinical trial failures."}},{"@type":"Question","name":"What drives NEU's share price?","acceptedAnswer":{"@type":"Answer","text":"NEU's share price is primarily driven by: 1) Quarterly sales figures and royalty revenue from DAYBUEâ„¢, 2) Clinical trial data and announcements for its pipeline drug NNZ-2591, and 3) Regulatory decisions from bodies like the US Food and Drug Administration (FDA)."}}]}6:["ticker","NEU","d"]
0:["eOdkiPUDvTtu3gxxCfEql",[[["",{"children":["asx",{"children":[["ticker","NEU","d"],{"children":["__PAGE__?{\"ticker\":\"NEU\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","NEU","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Neuren Pharmaceuticals Limited"," (","NEU",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Neuren Pharmaceuticals is an Australian biotechnology company developing therapies for rare and debilitating neurological disorders. Its first drug, trofinetide (marketed as DAYBUEâ„¢), is approved and sold in the United States for the treatment of Rett syndrome, generating significant royalty revenue. The company is advancing its pipeline candidate, NNZ-2591, through clinical trials for other serious conditions including Phelan-McDermid, Angelman, and Pitt Hopkins syndromes."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$1.9B"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"NEU"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Neuren has successfully transitioned from a development-stage to a commercial-stage biotechnology company following the US FDA approval and launch of DAYBUEâ„¢ by its partner Acadia Pharmaceuticals. The strong market uptake has resulted in substantial, high-margin royalty and milestone payments, significantly strengthening Neuren's balance sheet and leading to profitability. This recurring revenue stream has de-risked the company's financial position, allowing it to self-fund its pipeline development without needing to raise dilutive capital, a key differentiator in the biotech sector.",{"children":"Neuren has successfully transitioned from a development-stage to a commercial-stage biotechnology company following the US FDA approval and launch of DAYBUEâ„¢ by its partner Acadia Pharmaceuticals. The strong market uptake has resulted in substantial, high-margin royalty and milestone payments, significantly strengthening Neuren's balance sheet and leading to profitability. This recurring revenue stream has de-risked the company's financial position, allowing it to self-fund its pipeline development without needing to raise dilutive capital, a key differentiator in the biotech sector."}],["$","p","The company's primary growth driver and focus is now its pipeline drug, NNZ-2591. This drug is being investigated in multiple Phase 2 clinical trials for several rare neurological disorders, each representing a significant unmet medical need and a substantial commercial opportunity. Near-term catalysts for the share price are heavily tied to the read-outs from these trials. Success in any of these indications could trigger a major value inflection, while the established revenue from DAYBUE provides a financial foundation to support this long-term strategy.",{"children":"The company's primary growth driver and focus is now its pipeline drug, NNZ-2591. This drug is being investigated in multiple Phase 2 clinical trials for several rare neurological disorders, each representing a significant unmet medical need and a substantial commercial opportunity. Near-term catalysts for the share price are heavily tied to the read-outs from these trials. Success in any of these indications could trigger a major value inflection, while the established revenue from DAYBUE provides a financial foundation to support this long-term strategy."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Recurring, high-margin royalty revenue from US sales of DAYBUEâ„¢ provides a strong and growing financial base.",{"children":["â€¢ ","Recurring, high-margin royalty revenue from US sales of DAYBUEâ„¢ provides a strong and growing financial base."]}],["$","li","Significant upside potential from its pipeline drug NNZ-2591, which targets multiple rare neurodevelopmental disorders, creating several 'shots on goal'.",{"children":["â€¢ ","Significant upside potential from its pipeline drug NNZ-2591, which targets multiple rare neurodevelopmental disorders, creating several 'shots on goal'."]}],["$","li","Strong balance sheet with substantial cash reserves and no debt, eliminating near-term financing risk and funding all planned clinical development.",{"children":["â€¢ ","Strong balance sheet with substantial cash reserves and no debt, eliminating near-term financing risk and funding all planned clinical development."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","High dependency on clinical trial outcomes for NNZ-2591, where failure in any of the trials would significantly impact future growth prospects and valuation.",{"children":["â€¢ ","High dependency on clinical trial outcomes for NNZ-2591, where failure in any of the trials would significantly impact future growth prospects and valuation."]}],["$","li","Revenue concentration risk, as current income is derived from a single product (DAYBUEâ„¢) in a single market (US).",{"children":["â€¢ ","Revenue concentration risk, as current income is derived from a single product (DAYBUEâ„¢) in a single market (US)."]}],["$","li","Competition in the broader neurology space from larger, better-resourced pharmaceutical companies could emerge over the long term.",{"children":["â€¢ ","Competition in the broader neurology space from larger, better-resourced pharmaceutical companies could emerge over the long term."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Market Sentiment"}],["$","div",null,{"className":"mt-4 flex items-center gap-3","children":[["$","span",null,{"className":"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400","children":["ðŸŸ¡"," ","Mixed"]}],["$","span",null,{"className":"text-xs text-slate-500","children":["Score: ","","0.00"]}]]}],["$","div",null,{"className":"mt-4","children":[["$","div",null,{"className":"flex justify-between text-[10px] uppercase tracking-widest text-slate-500","children":[["$","span",null,{"children":"Bearish"}],["$","span",null,{"children":"Bullish"}]]}],["$","div",null,{"className":"relative mt-1 h-2 rounded-full bg-ink-900/60","children":[["$","div",null,{"className":"absolute left-1/2 top-0 h-full w-px bg-slate-600"}],["$","div",null,{"className":"absolute top-0 h-full w-2 rounded-full bg-yellow-500","style":{"left":"calc(50% - 4px)"}}]]}]]}],["$","div",null,{"className":"mt-4 flex gap-4 text-xs","children":[["$","span",null,{"className":"text-emerald-400","children":["â–² ",0," bullish"]}],["$","span",null,{"className":"text-red-400","children":["â–¼ ",0," bearish"]}],["$","span",null,{"className":"text-slate-500","children":[10," neutral"]}]]}],["$","p",null,{"className":"mt-1 text-xs text-slate-500","children":["Based on ",10," social post","s"]}],["$","div",null,{"className":"mt-4 space-y-2","children":[["$","p",null,{"className":"text-xs uppercase tracking-widest text-slate-500","children":"Recent mentions"}],[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Neuren Pharmaceuticals Limited"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to NEU"}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-05"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Neuren Pharmaceuticals Limited"}]]}]]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Priority Review Voucher program reauthorized by US Congress"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"4 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"General"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Neuren receives US FDA meeting feeback for HIE and PTHS"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"4 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Price Sensitive"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Neueren, a biotech company specializing in hormone therapies for osteoporosis, has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding their meeting discussions on Hydroxyapatite-Enriched In"}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Trading Halt"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"3 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Trading Halt"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"The Australian Securities Exchange has temporarily halted trading of the ticker symbol NEU due to a significant event or development that requires immediate attention and disclosure. Investors are advised to review their positions in light of this announcement, as it may impact market prices once normal"}]]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Pause in Trading"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"3 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Price Sensitive"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Neu Holdings Limited (NEU) has temporarily suspended trading on the Australian Securities Exchange due to an upcoming significant corporate event. Investors are advised to monitor updates closely as future actions and implications for their investments will be announced soon."}]]}],["$","div","4",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Acadia provides update on EU regulatory submission"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"2 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Progress Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"Acadia updates Australian investors with progress on its European Union regulatory filing, crucial for future market access and expansion."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does NEU do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does NEU do?"}],["$","p",null,{"className":"text-slate-400","children":"Neuren Pharmaceuticals is an Australian biotechnology company focused on developing treatments for rare neurological disorders. Their lead product, trofinetide (DAYBUEâ„¢), is approved in the US for Rett syndrome and generates royalty income, while their pipeline candidate, NNZ-2591, is in clinical trials for other neurodevelopmental conditions."}]]}],["$","div","Is NEU a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is NEU a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"Neuren represents a high-growth opportunity, having successfully commercialised its first drug, which provides a strong revenue stream. However, as a biotech company, its valuation is highly dependent on the success of its NNZ-2591 clinical trials, which carries significant binary risk. Investors should weigh the substantial upside potential from pipeline success against the inherent risks of clinical trial failures."}]]}],["$","div","What drives NEU's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives NEU's share price?"}],["$","p",null,{"className":"text-slate-400","children":"NEU's share price is primarily driven by: 1) Quarterly sales figures and royalty revenue from DAYBUEâ„¢, 2) Clinical trial data and announcements for its pipeline drug NNZ-2591, and 3) Regulatory decisions from bodies like the US Food and Drug Administration (FDA)."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","13.20"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["10.6","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$1.9B"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"03/02/2005"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/2fbff65d058c44b4.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"NEU share price, analysis & company profile - Neuren Pharmaceuticals Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest NEU share price overview, what Neuren Pharmaceuticals Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/NEU/"}],["$","meta","5",{"property":"og:title","content":"NEU share price, analysis & company profile - Neuren Pharmaceuticals Limited"}],["$","meta","6",{"property":"og:description","content":"Latest NEU share price overview, what Neuren Pharmaceuticals Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/NEU/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NEU share price, analysis & company profile - Neuren Pharmaceuticals Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest NEU share price overview, what Neuren Pharmaceuticals Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
